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Abstract 15	
Immunoglobulin E (IgE) represents the least abundant antibody isotype in human 16	
serum. Nevertheless, it has the ability to induce remarkably potent allergic reactions. 17	
As a key component in the development and manifestation of hypersensitivity 18	
responses against usually non-hazardous foreign substances, IgE has become a 19	
major target of investigation and the subject of multiple therapeutic approaches for the 20	
treatment of allergies. Recent advances in the understanding of pathophysiologic 21	
mechanisms underlying IgE-associated allergic disorders have led to the generation 22	
of new drug candidates that are currently in development or under clinical evaluation. 23	
In this review, we highlight molecular and structural mechanisms underlying the 24	
different anti-IgE molecules and suggest a concept of multi-level targeting using a new 25	
class of disruptive IgE inhibitors to potentially optimize treatment efficacy.  26	
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Introduction 27	
Since its discovery little more than 50 years ago, immunoglobulin E (IgE) has been 28	
attributed a wide variety of immunological functions including host defense against 29	
parasite infections and toxic venoms [1-3]. It has become increasingly evident that 30	
besides these beneficial properties IgE is a central player in the development and 31	
manifestation of allergic reactions [4]. Allergic rhinoconjunctivitis, atopic dermatitis, 32	
food allergies or allergic asthma are mostly IgE-dependent allergic conditions which 33	
manifest in symptoms ranging from mild local reactions to life-threatening systemic 34	
episodes. Generally, allergies are causing a marked reduction in quality of life and due 35	
to the low cost-effectiveness of targeted anti-IgE intervention strategies patients are 36	
often treated with unspecific therapeutics such as corticosteroids [5,6]. Recent 37	
advances in the understanding of basic molecular and structural properties of IgE and 38	
its receptors have helped to develop more targeted treatment approaches (Table 1) 39	
that we highlight in this review. 40	
 41	
Structure-function relationship in IgE and its receptors 42	
As a heterodimeric glycoprotein IgE consists of two light and two heavy chains. The 43	
heavy chain Fc-region of IgE (IgE-Fc) contains three consecutive Ig-domains, termed 44	
Cε2-4 (Figure 1a). Compared to other immunoglobulins it lacks a flexible hinge region 45	
and thus adopts a rigid bent conformation in solution in which the Cε2 domain of both 46	
heavy chains asymmetrically fold back onto the Cε3 domain [7]. IgE exerts its effector 47	
functions through mutually exclusive interactions with its two principal cell surface 48	
receptors FcεRI and CD23 [8].  49	
The high-affinity IgE receptor FcεRI is expressed as an αβγ2 heterotetramer primarily 50	
on human basophils and mast cells and as an αγ2 heterotrimer on human dendritic 51	
cells and monocytes [9]. FcεRIα binds IgE-Fc via two distinct interaction-sites [10]. 52	
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While the Cε3 domains are in direct contact with the receptor, the Cε4 domains form a 53	
heavy chain dimerization interface. The 1:1 complex between IgE and FcεRIα is of 54	
remarkably high affinity (KD~ 10-9-10-10 M). Crystallization experiments have revealed 55	
that IgE undergoes a large conformational change upon FcεRIα binding in which the 56	
Cε3:Cε4 interdomain angle significantly increases (Figure 1b)  [11]. This FcεRIα-57	
bound IgE-Fc arrangement is referred to as open conformation (Figure 1c) [10,12]. 58	
Moreover, upon binding of FcεRIα the Cε2 domains increase their back-folding onto 59	
the Cε3 domain which further aggravates the asymmetrically bent conformation of IgE 60	
(Figure 1d) [11]. Interestingly, the Cε2 domains are not necessary for FcεRIα binding, 61	
but slow down both on and off rates for FcεRIα engagement [13]. Functionally, allergen 62	
induced cross-linking of FcεRI-bound IgE stimulates degranulation of basophils and 63	
mast cells that results in the release of pre-stored as well as de novo synthesized pro-64	
inflammatory and vasoactive mediators inducing classical symptoms of an allergic 65	
disorder [14]. 66	
The second IgE cell surface receptor is CD23. Due to its carbohydrate binding head 67	
domain, it belongs to the C-type lectin superfamily [15]. Even though IgE is one of the 68	
most glycosylated mammalian immunoglobulins, binding to CD23 has been shown to 69	
be independent of lectin-glycan interactions [16,17]. Since monomeric IgE:CD23 70	
complexes are typically unstable (KD~ 10-6 - 10-7 M) CD23 is also referred to as low-71	
affinity IgE receptor [18]. The presence of Ca2+ substantially enhances the affinity for 72	
IgE about 30-fold through the induction of conformational changes in the receptor 73	
[19,20]. Crystal structures have revealed that binding of IgE occurs via the CD23 head 74	
domain in a 2:1 stoichiometry (Figure 1e) [8,21]. A study using negative stain electron 75	
microscopy has recently described an additional contribution of the CD23 stalk region 76	
to IgE binding [22]. Given the asymmetric bent conformation of IgE, it has been 77	
reported that the two CD23 interaction sites have different binding kinetics and affinities 78	
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[21]. Upon CD23 binding the IgE-Fc adopts a closed conformation in which the Cε3-79	
Cε4 interdomain angle significantly decreases (Figure 1f). CD23 is mainly expressed 80	
on B-cells, epithelial cells as well as antigen-presenting cells and multiple studies have 81	
highlighted the role of CD23 in the regulation of IgE synthesis as well as allergen 82	
transport and presentation [23,24].  83	
 84	
Classical inhibition of free serum IgE 85	
Omalizumab, also known as XolairÒ, is a humanized monoclonal anti-IgE antibody that 86	
has initially been approved for the treatment of moderate to severe persistent allergic 87	
asthma [25] including children ≥ 6 years of age [26]. More recently, it has been 88	
authorized for the use in patients with chronic spontaneous urticaria [27]. Additionally, 89	
off-label use of Omalizumab has revealed its efficacy in facilitating allergen updosing 90	
and desensitization in allergen-specific immunotherapy [28,29]. Omalizumab binds IgE 91	
with high affinity (KD~ 7 x 10-9 M) [30]. Its primary mode of action is the neutralization 92	
and clearance of free serum IgE which further results in the destabilization and loss of 93	
FcεRI on mast cells and basophils [31]. Interestingly, treatment with Omalizumab has 94	
also been shown to reduce the number of circulating basophils [32]. Crystal structures 95	
of Omalizumab with a closed conformation IgE-G335C-Fc3-4 mutant helped to 96	
precisely map the binding-site of Omalizumab to the Ce3 domain of IgE (Figure 1g) 97	
and revealed that the inhibition of IgE binding to FcεRI is due to steric conflicts of the 98	
Omalizumab light-chain with FcεRIα, while there is barely any direct competition for 99	
FcεRIα binding residues [33]. An alternative possibility of Omalizumab-mediated 100	
inhibition of IgE:FceRI complex formation has recently been suggested [34]. The 101	
authors of this study propose an allosteric mechanism in which Omalizumab binding 102	
induces an unbending of IgE that is associated with structural changes compromising 103	
FcεRI binding. Both studies agree that Omalizumab prevents binding of IgE to CD23, 104	
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which is dependent on direct competition for receptor-binding residues on IgE as well 105	
as major steric clashes between CD23 and Omalizumab [33]. Even though a recent 106	
study has reported that CD23 surface levels on B-cells of allergic patients correlate 107	
with allergen-specific IgE levels it remains elusive whether Omalizumab treatment has 108	
a direct effect on IgE-production in B-cells through inhibition of IgE:CD23 interaction 109	
[35].  110	
QGE031, also known as Ligelizumab, is a humanized high-affinity anti-IgE antibody 111	
that is based on the previously developed CGP51901 antibody (i.e. Talizumab or TNX-112	
901). Compared to Omalizumab, Ligelizumab binds IgE with significantly higher affinity 113	
(KD~ 1.4 x 10-10 M) and suppresses IgE serum levels with six- to nine-fold higher 114	
potency [30]. Further, the reduction of cell surface IgE on circulating basophils is more 115	
sustained and the inhibition of skin prick responses to allergens is more pronounced 116	
upon Ligelizumab treatment. Despite promising results in a phase I study with mild 117	
allergic asthma patients (NCT01703312) [36], the phase 2 study with asthma patients 118	
(NCT02336425) has been discontinued. A phase 2b study, testing the efficacy and 119	
safety of Ligelizumab in patients with chronic spontaneous urticaria has recently been 120	
completed (NCT02477332) and results are pending. 121	
Another anti-IgE antibody, called MEDI4212, has been engineered from a single-chain 122	
variable fragment selected against IgE using phage display [37]. It binds IgE with even 123	
higher affinity than Ligelizumab (KD~ 2 x 10-12 M) and also inhibits binding to FcεRIα 124	
[37]. Further, MEDI4212 has been shown to inhibit IgE binding to CD23 on B-cells in 125	
vitro. Crystal structures of MEDI4212 in complex with IgE-Fc3-4 helped to map its 126	
interaction-site to the Ce3 domain of IgE and showed that it directly competes with 127	
FceRIα but not CD23 binding residues on IgE (Figure 1h). This study suggests that 128	
MEDI4212 locks IgE in an open conformation which is unable to bind CD23 [37]. In a 129	
Phase 1 clinical trial (NCT01544348) MEDI4212 showed superior results in 130	
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suppressing IgE levels compared to Omalizumab [38]. However, IgE levels returned 131	
to baseline faster in MEDI4212 treated patients, which might be due to its shorter 132	
serum half-life. 133	
 134	
Targeting IgE producing B cells 135	
Cross-linking of the  B-cell receptor (BCR) without co-stimulation has been reported to 136	
induce apoptosis [39]. To exploit this mechanism and to test whether targeting and 137	
depletion of IgE producing B-cells might represent a suitable therapeutic strategy to 138	
decrease serum IgE levels an antibody specific for the membrane proximal domain 139	
(M1) of the IgE BCR has been developed [40]. This antibody, initially termed 47H4, 140	
successfully reduced the number of IgE expressing B-cells and decreased serum IgE 141	
levels in mice. Since afucosylation of antibodies increases their affinity to FcyRIIIA on 142	
NK-cells and thereby enhances the potentcy of antibody dependent cellular cytotoxicity 143	
(ADCC) a humanized, afucosylted version of 47H4, called Quilizumab, has been 144	
generated and tested in humans with allergic conditions. Quilizumab treatment of 145	
patients with allergic rhinitis and mild allergic asthma reduced baseline allergen-146	
specific and total IgE in serum up to 30% in a phase 1b (NCT01160861) and 2a 147	
(NCT01196039) clinical trial [41]. These reductions were sustained for at least 6 148	
months. While a significant amelioration of the allergen-induced symptoms in the early-149	
asthmatic response to airway challenge was observed, no improvement was apparent 150	
for the late asthmatic response. In another phase 2 study in adults with inadequately 151	
controlled asthma (NCT01582503) no clinical significant improvement was achieved 152	
upon Quilizumab treatment [42]. Moreover, an additional phase 2 study in adults with 153	
refractory chronic spontaneous urticaria (NCT01987947) failed to demonstrate 154	
significant clinical efficacy of Quilizumab [43]. 155	
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Recently, modified versions of the monoclonal anti-IgE antibody MEDI4212 with 156	
improved binding to FcyRIIIA have been engineered. While the reactivity against IgE 157	
remained unchanged the elimination of IgE expressing B-cells in vitro was significantly 158	
increased [44]. The afucosylated variant of MEDI4212 decreased serum IgE levels in 159	
a humanized mouse model to a higher degree than the fucosylated variant [44]. No 160	
clinical human data is currently available for the afucosylated variant of MEDI4212. 161	
 162	
Disruptive IgE inhibitors – a new class of anti-IgE molecules 163	
In 2012, a new and promising class of anti-IgE molecules with the ability to not only 164	
neutralize free IgE but in addition actively dissociate pre-formed IgE:FcεRI complexes 165	
has been reported [45,46]. The disruptive IgE inhibitor, termed DARPin® E2_79, and 166	
its improved bivalent version, DARPin® bi53_79, have been demonstrated to 167	
desensitize allergic effector cells by actively removing IgE from their cell surface [47]. 168	
This mechanism - termed facilitated dissociation - differs from the classic competitive 169	
and the allosteric inhibition model [48]. It represents a competitor-induced dissociation 170	
mechanism in which the binding site on a ligand becomes exposed during partial 171	
ligand:receptor complex dissociation [46]. Interestingly, it has been shown in these 172	
studies that Omalizumab also accelerates the dissociation of IgE:FcεRI - however, only 173	
at very high concentrations [47]. Recently, the disruptive activity of Omalizumab has 174	
been enhanced by introducing three point-mutation into the variable light and constant 175	
domain of its Fab fragment, called FabXol3 [34]. The binding sites of FabXol3 and 176	
DARPin® E2_79 on the Ce3 domain of IgE are overlapping and of similar size (Figure 177	
1I, J). While E2_79 is acting through facilitated dissociation [46], an allosteric 178	
mechanism has been proposed for FabXol3 [34].  179	
Further, a llama-derived humanized single-domain antibody, named 026 sdab, has 180	
been described to inhibit IgE binding to FceRI through an allosteric mechanism by 181	
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trapping IgE in a closed conformation [49]. The crystal structure of 026 sdab with IgE-182	
Fc3-4 revealed no overlap with FcεRI binding sites but significant competition with CD23 183	
attachment points on IgE. 026 sdab binds IgE with high affinity (KD~ 1.4 x 10-9 M) and 184	
has the ability to disrupt pre-formed IgE:FcεRI complexes (Figure 1k). In line with the 185	
observed removal of surface IgE, 026 sdab decreased basophil allergen-sensitivity. 186	
Furthermore, 026 sdab has been shown to inhibit binding of IgE:allergen complexes to 187	
CD23. 188	
Similar to the disruptive IgE inhibitor DARPin® E2_79, the bivalent anti-IgE/ anti-HSA 189	
Nanobody® ALX-0962 has been reported to neutralize free IgE and remove FcεRI-190	
bound IgE from human primary basophils [50]. In various studies, it has been 191	
speculated that disruptive inhibitors might show faster onset of action compared to 192	
conventional anti-IgE molecules and thereby accelerate treatment benefits. 193	
 194	
Conclusions 195	
In summary, we have highlighted various anti-IgE approaches to interfere with the 196	
allergic cascade on multiple levels (Figure 2a). While the neutralization of free serum 197	
IgE represents the oldest and most advanced therapeutic strategy, recent studies have 198	
paved the way for alternative treatment approaches. Targeting of IgE producing B-cells 199	
has gained a lot of momentum. However, it is most likely due to the low frequency, the 200	
short half-live and the anatomic location of IgE bearing B-cells that this strategy has 201	
shown limited success in clinical trials so far. Disruptive IgE inhibitors that in addition 202	
to the neutralization of free IgE actively desensitize antigen-presenting or allergic 203	
effector cells are the most recent development in the anti-IgE field. It will be interesting 204	
to see whether and how this additional mode of action might translate into patient 205	
benefit. The development of a molecule that efficiently targets the allergic cascade at 206	
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multiple levels and unifies different modes of action (Figure 2b) might be an attractive 207	
way to improve the treatment efficacy for allergic disorders in the future. 208	
  209	
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Table 1. 210	
 Omalizumab Ligelizumab MEDI4212 Quilizumab bi53_79 026 sdab 
Class IgG1 k IgG1 k IgG1 λ IgG1 k DARPin* single-domain antibody 
Affinity constant KD 
[M] 7 x 10
-9 M 1.4 x 10-10 M 2 x 10-12 M ? 12 x 10-9 M 1.4 x 10-9 M 
Free IgE binding + ++ +++ - + + 
IgE:FcεRIα complex 
disruption + ? ? - +++ ++ 
FcεRIα inhibition + ++ +++ - + + 
CD23 inhibition + ? + - + + 
IgE+ B-cells 
elimination - ? + + ? ? 
References [25,33,34,47] [30,36] [37,38,44] [40-43] [33,46,47] [49] 	211	
* DARPin = Designed Ankyrin Repeat Protein; + = positive evidence; - = negative evidence; ? = unknown   212	
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Figure Legends 213	
 214	
Figure 1. Structural representations of IgE-Fc variants alone or in complex with 215	
the indicated receptors or anti-IgE molecules. The two IgE-Fc heavy chains are 216	
represented in yellow and black, while IgE receptors and anti-IgE molecules are 217	
colored in red or red/orange. (a) Asymmetrically bent conformation of IgE-Fc2-4, PDB-218	
ID: 1O0V; (b) Complexed FcεRIα:IgE-Fc3-4, PDB-ID: 1F6A; (c) Open conformation of 219	
IgE-Fc3-4, PDB-ID: 3HA0; (d) Complexed FcεRIα:IgE-Fc2-4, PDB-ID: 2Y7Q; (e) 220	
Complexed CD23:IgE-Fc3-4, PDB-ID: 4EZM; (f) Closed conformation of IgE-Fc3-4, 221	
PDB-ID: 3H9Z; (g) Complexed Omalizumab Fab:IgE-G335C-Fc3-4, PDB-ID: 5HYS; (h) 222	
Complexed MEDI4212:IgE-Fc3-4, PDB-ID: 5ANM. Structure is vertically turned 90° to 223	
the left compared to all other images; (i) Complexed DARPin E2_79:IgE-Fc3-4, PDB-224	
ID: 4GRG; (j) Complexed FabXol3:IgE-Fc2-4, PDB-ID: 5G64; (k) Complexed 026 225	
sdab:IgE-Fc3-4, PDB-ID: 5NQW. 226	
 227	
Figure 2. Anti-IgE intervention strategies. During allergic sensitization, activated 228	
isotype switched B-cells (B) produce allergen-specific IgE, which is released into the 229	
circulation. Soluble free IgE may bind to the low affinity IgE-receptor CD23 expressed 230	
on B-cells or to the high affinity IgE-receptor FcεRIα expressed on allergic effector cells 231	
such as basophils (Ba) in the blood. (a) The primary mode of action for the anti-IgE 232	
antibodies Omalizumab, Ligelizumab and MEDI4212 is the neutralization and 233	
clearance of soluble IgE (red solid lines). Omalizumab and MEDI4212 also inhibit 234	
binding of IgE to CD23 (dashed lines). Further, Omalizumab accelerates the 235	
dissociation of IgE from FcεRIα (dashed line), while the afucosylated version of 236	
MEDI4212 aims to target and eliminate IgE+ B-cells. Quilizumab targets the membrane 237	
proximal M1 domain on IgE+ B-cells and eliminates these cells by ADCC; black star: 238	
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improved FcγRIIA binding. (b) We propose, that an anti-IgE molecule which interferes 239	
with the allergic cascade at multiple levels would achieve maximal therapeutic efficacy. 240	
Ideally, such a molecule would neutralize soluble IgE, actively dissociate pre-formed 241	
IgE:FcεRIα complexes on the surface of sensitized allergic effector cells and target 242	
IgE-producing B-cells to inhibit IgE-synthesis.  243	
  244	
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